abrdn plc Sells 419,726 Shares of uniQure (NASDAQ:QURE)

abrdn plc lessened its position in shares of uniQure (NASDAQ:QURE) by 21.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,509,335 shares of the biotechnology company’s stock after selling 419,726 shares during the quarter. abrdn plc’s holdings in uniQure were worth $26,655,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Franklin Resources Inc. purchased a new stake in uniQure during the third quarter valued at $7,360,000. Point72 Asset Management L.P. increased its position in uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after acquiring an additional 752,889 shares during the last quarter. Privium Fund Management B.V. increased its position in uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after acquiring an additional 104,500 shares during the last quarter. Geode Capital Management LLC increased its position in uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after acquiring an additional 6,362 shares during the last quarter. Finally, FMR LLC increased its position in uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after acquiring an additional 346,274 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

QURE has been the subject of a number of research reports. Mizuho upped their price objective on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 19th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. The Goldman Sachs Group upped their price target on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Leerink Partners upped their price target on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.74% of the stock is owned by corporate insiders.

uniQure Stock Performance

NASDAQ:QURE opened at $16.13 on Thursday. The stock has a 50-day moving average price of $14.29 and a 200 day moving average price of $9.09. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The stock has a market capitalization of $786.18 million, a P/E ratio of -3.25 and a beta of 0.39. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. Equities research analysts forecast that uniQure will post -3.75 EPS for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.